OMNIlife Science
-
Robotics
OMNIlife Science Inc., Named 2019 DOCSF Innovation Award Winner
SAN FRANCISCO (PRWEB) JANUARY 10, 2019 OMNIlife science, Inc. (“OMNI”) has been named the winner of the DOCSF Innovation Award. Eight…
Read More » -
Recon
OMNIlife science™, Inc. Achieves Milestone with OMNIBotics® Active Spacer
RAYNHAM, Mass., Oct. 3, 2018 /PRNewswire/ — OMNIlife science, Inc. (“OMNI”), a privately-held, medical technology company targeting the $15 billion global hip and knee replacement…
Read More » -
Recon
Brigham Redd, M.D. is first surgeon in Idaho to offer OMNIBotics® Robotic-assisted Total Knee Replacement
RAYNHAM, Mass., Aug. 8, 2018 /PRNewswire/ — OMNIlife science, Inc. (“OMNI”), a privately-held, established medical technology company targeting the $15 billion global hip and knee…
Read More » -
Recon
New Data and Surgical Experiences with OMNIBotics® Active Spacer™ Ligament Balancing System Presented at Prestigious Orthopaedics Conference
RAYNHAM, Mass., Feb. 5, 2018 /PRNewswire/ — OMNIlife science™, Inc. (“OMNI™”), an established medical technology company targeting the $15 billion global hip and knee…
Read More » -
Recon
OMNIlife science™, Inc. Announces First Clinical Evaluations of Revolutionary OMNIBotics® Active Spacer Robotic Tissue Balancing Device
RAYNHAM, Mass., Oct. 31, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), a privately-held, established medical technology company targeting the $15 billion global hip and…
Read More » -
Recon
OMNIlife science™, Inc. Surpasses 17,000 Procedures Milestone for OMNIBotics® Robotic-Assisted Total Knee Replacements
RAYNHAM, Mass., Oct. 5, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), an established medical technology company targeting the $15 billion global hip and knee replacement…
Read More » -
Hospitals
OMNIlife science™, Inc. Receives 510(k) Clearance from FDA for Revolutionary Robotic Tissue Balancing Device
AYNHAM, Mass., Sept. 6, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), a privately-held, established medical technology company targeting the $15 billion global hip and…
Read More » -
Hospitals
OMNIlife science™, Inc. Announces First Clinical Use of Novel Robotic Tissue Balancing Device for OMNIBotics® Technology Platform
RAYNHAM, Mass., March 13, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), a privately-held, established medical technology company targeting the $15 billion…
Read More »